Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG).

ABSTRACT:

Background

A urine concentrating defect is quite common in sickle cell anemia, has its onset in early childhood, and may be reversible with transfusion. The Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) is a double-blind, placebo-controlled trial to assess efficacy of hydroxyurea in preventing organ damage in young children with sickle cell anemia.

Procedures

Enrolled infants were subjected to parent-supervised fluid deprivation, and urine and serum osmolality were determined.

Results

Of 185 infants age 7.5-17.9 months (mean 13.0 +/- 2.7) and fluid-deprived 7.4 +/- 2.4 hr (range 4-13), 178 had concurrent determinations of urine and serum osmolality. Mean serum osmolality was 286 +/- 6 mOsm/kg H(2)O (range 275-312) and independent of age, height, weight, or

SUBMITTER: Miller ST 

PROVIDER: S-EPMC2795020 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature